Omeros Corporation (Nasdaq: OMER) today announced two presentations that will be featured at the 2025 Tandem Meetings – the ...

Omeros’ first-in-class monoclonal antibody inhibiting the lectin pathway of complement, in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a ...

Endothelial damage, which activates the lectin pathway of complement, plays a central role in the development of TA-TMA. The condition occurs in both autologous and allogeneic transplants but is ...

A study on COVID-19 patients highlighted the role of MASP-2 in the lectin pathway of complement activation. The researchers developed a sensitive assay to measure MASP-2 levels and found that its ...

and ficolins allowing classical and lectin pathway activation, C3 convertase, C4b2a generation, and C3 cleavage. Opsonization due to covalent binding of C3b to the target is accelerated by the ...

Complement fixation is activated through three protease cascade pathways: the classical, the alternative and the mannan-binding lectin pathway 101. All pathways involve the cleavage of complement ...

Narsoplimab, also known as OMS721, is a monoclonal antibody targeting MASP-2, a key player in the lectin pathway of the complement system. The drug has received breakthrough therapy and orphan ...

FGF21 regulates Th17-mediated inflammation through the STAT3/RORγt pathway. The interaction of LECT2 with ... after activation by the classical, alternative, and lectin pathways. All complement ...

Published in Cell Reports Medicine, results of a VHIO-led study support the feasibility of using RAD51 testing to complement ...